339 20 mg Pill - orange capsule/oblong, 18mm
Pill with imprint 339 20 mg is Orange, Capsule/Oblong and has been identified as Amphetamine and Dextroamphetamine Extended-Release 20 mg. It is supplied by Sun Pharmaceutical Industries Inc.
Amphetamine/dextroamphetamine is used in the treatment of ADHD; Narcolepsy and belongs to the drug class CNS stimulants. Risk cannot be ruled out during pregnancy. Amphetamine/dextroamphetamine 20 mg is classified as a Schedule 2 controlled substance under the Controlled Substance Act (CSA).
Images for 339 20 mg
Amphetamine and Dextroamphetamine Extended-Release
- Imprint
- 339 20 mg
- Strength
- 20 mg
- Color
- Orange
- Size
- 18.00 mm
- Shape
- Capsule/Oblong
- Availability
- Prescription only
- Drug Class
- CNS stimulants
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- 2 - High potential for abuse
- Labeler / Supplier
- Sun Pharmaceutical Industries Inc.
- Manufacturer
- Ohm Laboratories Inc.
- National Drug Code (NDC)
- 57664-0339
More about amphetamine / dextroamphetamine
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1,159)
- Drug images
- Latest FDA alerts (4)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: CNS stimulants
- En español
Patient resources
- Amphetamine and dextroamphetamine drug information
- Dextroamphetamine and amphetamine (Advanced Reading)
- Dextroamphetamine and Amphetamine Tablets
- Dextroamphetamine and Amphetamine Extended-Release Capsules (Adderall XR)
- Dextroamphetamine and Amphetamine Extended-Release Capsules (Mydayis)
Other brands
Adderall, Adderall XR, Mydayis
Professional resources
- Amphetamine monograph
- Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate (FDA)
- Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate ER Capsules (FDA)
Other brands
Adderall, Adderall XR, Mydayis
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
